Option chain shows key data for Greenwich LifeSciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Greenwich LifeSciences.

Greenwich LifeSciences (NASDAQ:GLSI) Stock, Option Chain

Greenwich LifeSciences

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.

Wall Street US stocks

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

EVBN

GLSI

UBFO

Over $1M Bet On United Security Bancshares? Check Out These 3 Stocks Insiders Are Buying

Small Cap

HROW

Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades.

Insiders Buying Greenwich LifeSciences And 2 Other Stocks

man-2425121

Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01.

Why Greenwich Lifesciences (GLSI) Stock Is Skyrocketing

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences Inc

Abacus intends to use net proceeds of the primary portion of the offering for its operations, including the purchase of life settlement policies, to support its overall business strategy, for working capital purposes, and for general corporate purposes, which may include funding previously announced and future acquisitions and repayment and refinancing of its indebtedness. Abacus will receive no proceeds from the secondary portion of the offering.

Reported Earlier, Abacus Life Prices $100M Public Offering Of 12.5M Common Shares At $8 Per Share

President-elect Donald Trump&#8216;s <a href="https://www.msn.com/en-us/money/news/trumps-doge-with-musk-at-the-helm-riddled-with-conflicts-of-interest-says-clinton-era-official-robert-reich/ar-AA1u3Joj">appointed DOGE</a> or the Department of Government Efficiency could potentially save $50–100 billion annually, according to Congressional Budget Office (CBO) analyses, said Mario Georgiou, CFA and executive director, head of investments at InCred Global Wealth U.K.
What Happened: Georgiou said that DOGE &#8220;tasked with cutting wasteful spending, could play a role in improving fiscal discipline, but the scale of potential savings is expected to be modest.&#8221;
The U.S. federal budget deficit could reach $1.7 trillion in 2024, entailing mandatory spending on Social Security and Medicare, which accounts for over 60% of expenditures, Georgiou said. &#8220;Even if the DOGE achieves its objectives, potential savings are estimated at $50–100 billion annually, according to Congressional Budget Office analyses, which would have only a marginal impact compared to total federal outlays of approximately $6.7 trillion in 2024,&#8221; he added.
However, Tesla Inc. and SpaceX CEO Elon Musk <a href="https://www.benzinga.com/news/24/11/42069803/elon-musks-doge-job-applications-require-x-premium-subscription">who will co-lead DOGE</a> with Republican politician Vivek Ramaswamy had called for &#8220;at least $2 trillion&#8221; in budget cuts last month while speaking at a rally in New York.
On Wednesday, Musk and Ramaswamy outlined their vision for DOGE, &#8220;The two of us will advise DOGE at every step to pursue three major kinds of reform: regulatory rescissions, administrative reductions, and cost savings,&#8221; the duo wrote in a <a href="https://www.wsj.com/opinion/musk-and-ramaswamy-the-doge-plan-to-reform-government-supreme-court-guidance-end-executive-power-grab-fa51c020">WSJ</a> opinion piece on Nov. 20.
Why It Matters: In their opinion piece, the duo said &#8220;DOGE will help end federal overspending by aiming $500 billion-plus in annual federal expenditures that are unauthorized by Congress or being used in ways that Congress never intended.&#8221;
Musk and Ramaswamy aimed a few expenditure programs along with $300 million provided to the other &#8220;progressive groups.&#8221; They mentioned $535 million allotted to the Corporation for Public Broadcasting and $1.5 billion in grants to Planned Parenthood annually.
Discretionary spending—where most inefficiencies and &#8220;waste&#8221; are typically identified, &#8220;constitutes a smaller portion of the budget and offers limited opportunities for impactful cuts​​,&#8221; Georgiou added.
Musk and Ramaswamy highlighted that several federal contracts have gone unexamined for years. They suggested that a temporary suspension of payments would facilitate comprehensive audits, resulting in substantial cost savings.
&#8220;The Pentagon recently failed its seventh consecutive audit, suggesting that the agency's leadership has little idea how its annual budget of more than $800 billion is spent.&#8221;
Also read: <a href="https://www.benzinga.com/markets/equities/24/11/42105450/elon-musk-says-amazon-founder-jeff-bezos-urged-tesla-spacex-investors-to-dump-stakes-predicting-trumps-loss">Elon Musk Says Amazon Founder Jeff Bezos Urged Tesla, SpaceX Investors To Dump Stakes, Predicting Trump&#8217;s Loss</a>
&#8220;We are focused on delivering cost savings for taxpayers,&#8221; the duo said in their piece.
Musk and Ramaswamy swiftly defended their stance on cutting the budgets of a few entitlement programs. &#8220;Critics claim that we can't meaningfully close the federal deficit without aiming for entitlement programs like Medicare and Medicaid, which require Congress to shrink. But this deflects attention from the sheer magnitude of waste, fraud, and abuse that nearly all taxpayers wish to end,&#8221; they added.
Read next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42130859/as-trump-backs-drill-baby-drill-his-doge-co-lead-elon-musk-believes-all-energy-generation-will-be-solar-heres-what-ubs-recommends-after-election-dip">As Trump Backs &#8216;Drill Baby, Drill,&#8217; His DOGE Co-Lead Elon Musk Believes &#8216;All Energy Generation Will Be Solar&#8217; — Here&#8217;s What UBS Recommends After Election Dip</a>
Image via Wikimedia Commons

Government

Macro Economic Events

Macro Notification

Regulations

Entrepreneurship

Politics

Economics

General

Donald Trump's DOGE Initiative To Have 'Marginal Impact' Says Analyst As Elon Musk Aims To Target Over $500B In Federal Expenditures

Meritage also announced that its Board of Directors has approved a $250 million increase to the Company's share repurchase authorization. This increase combined with $15 million in systematic buybacks on a quarter to date basis brings the Company's total authorized share repurchase program to $334 million as of November 21, 2024.

Reported Earlier, Meritage Homes Declares $0.75 Dividend And Expands Share Buyback By $250M

Total Revenue was ¥18.9 billion for the fiscal year ended June 30, 2024, from ¥17.4 billion for the fiscal year ended June 30, 2023.
The major revenue component, Real Estate Sales, increased to ¥18.5 billion from ¥17.1 billion, 8.1% year over year, in the fiscal year ended June 30, 2024.

Earnings

Reported Earlier, Lead Real Estate Reported FY24 EPS ¥46.93 Down From ¥48.96 YoY, Revenue ¥18.9B Up From ¥17.4B YoY

The gross proceeds of the offering are expected to be $12.1 million, excluding the exercise of the underwriter's option, if any, of approximately $1.8 million, and excluding underwriting discounts and commissions and other offering-related expenses. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital.

KSCP

Reported Earlier, Knightscope Prices $12.1M Public Offering Of 1.21M Class A Common Stock At $10/Share

Econ #s

Germany Gross Domestic Product (YoY) For Q3 -0.3% Vs. -0.2% Est.; -0.2% Prior

Germany Gross Domestic Product (QoQ) For Q3 0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Retail Sales (MoM) For October -0.7% Vs. -0.3% Est.; 0.1% (Revised) Prior

U.K. Retail Sales (YoY) For October 2.4% Vs. 3.4% Est.; 3.2% (Revised) Prior

U.K. Core Retail Sales (YoY) For October 2.0% Vs. 3.3% Est.; 3.2% (Revised) Prior

U.K. Core Retail Sales (MoM) For October -0.9% Vs. -0.3% Est.; 0.1% (Revised) Prior

The Securities and Exchange Commission&#8217;s (SEC) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098407/donald-trump-reportedly-eyeing-the-first-crypto-focused-role-in-the-white-house">lawsuits against cryptocurrency companies</a> will likely reach settlements once Chair Gary Gensler steps down in January 2025, according to crypto asset manager Pantera&#8216;s chief legal officer Katrina Paglia.
What Happened: Speaking at the North American Blockchain Summit in Dallas on Thursday, Paglia <a href="https://cointelegraph.com/news/sec-lawsuits-quietly-go-away-after-gensler-steps-down-pantera-clo">said</a>, according to Cointelegraph that while the SEC won&#8217;t completely withdraw its claims, many cases will &#8220;quietly go away&#8221; with defendants paying settlements under &#8220;neither admit nor deny&#8221; terms.
&#8220;The regulator will get to make some level of a statement and get something for the value of time and energy spent,&#8221; Paglia said, noting this would be &#8220;very beneficial&#8221; for resolving the extensive litigation.
The comments come as President-elect Donald Trump&#8216;s transition team actively shapes what appears to be a dramatically different approach to crypto regulation. 
See Also: <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">Bitcoin Analyst Warns Of &#8216;4-6 Flash Crashes&#8217; Before Year-End As It Inches Closer To $100K: That&#8217;s The Moment Altcoins &#8216;Shoot Off&#8217;</a>
Why It Matters: The incoming administration is reportedly vetting candidates for the first-ever White House <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098407/donald-trump-reportedly-eyeing-the-first-crypto-focused-role-in-the-white-house">cryptocurrency policy role</a> while major industry players like Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) CEO Brian Armstrong engage in <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42114875/coinbase-ceo-brian-armstrong-stands-out-as-candidate-for-donald-trumps-reported-crypto-czar-position-cardano-co-founder-says">high-level discussions</a>.
Industry experts see the potential for <a href="https://www.benzinga.com/24/11/42069770/us-congress-could-set-the-stage-for-broader-crypto-adoption-says-digital-asset-leader">significant policy shifts</a>, with Hunting Hill Global Capital&#8216;s CIO Adam Guren emphasizing the need for &#8220;thoughtful policy&#8221; and clear definitions for digital assets. &#8220;Well-defined classifications would encourage engagement from both individual and institutional investors,&#8221; Guren noted.
The market has responded positively to these developments, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">approaching $100,000</a> amid reports that companies including Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Kraken, and Circle (CRYPTO: USD) are seeking representation on <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122348/trumps-planned-crypto-council-may-oversee-bitcoin-reserve-report">Trump&#8217;s promised crypto advisory council</a>.
The SEC under Gensler&#8217;s leadership has pursued actions against numerous high-profile crypto companies, including Ripple, Binance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), Kraken, and others, in what many in the industry have characterized as an aggressive regulatory approach.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">Bitcoin&#8217;s Path To $100K &#8216;Inevitable&#8217; But Crypto Community Is &#8216;Leveraged To The Gills,&#8217; Warns Galaxy&#8217;s Mike Novogratz, Predicts Correction To $80K Ahead</a></li>
</ul>
SEC Gary Gensler. Photo by Third Way Think Tank on Flickr
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$XRP

COIN

As Gary Gensler Eyes 2025 Exit, SEC Crypto Cases Could 'Quietly Disappear' Under Trump's Pro-Bitcoin Agenda, Says Pantera Capital's Katrina Paglia

The Company intends to use net proceeds from the offering for general corporate purposes, which may include new debt and equity investment opportunities and the repayment of a portion of its outstanding indebtedness.

Reported Earlier, SL Green Realty Prices 5,063,291 Common Shares At $79/Share

The billionaire Republican megadonor and Citadel CEO Ken Griffin has expressed openness to selling a minority stake in the $65 billion hedge fund he established in 1990.
What Happened: Griffin has previously sold stakes in his ventures. Two years ago, Sequoia Capital acquired a stake in Citadel Securities for $1.15 billion, valuing the market maker at $22 billion. Recently, Citadel Securities received a $5 billion investment offer from a private equity firm, which Griffin mentioned would help the company remain private longer.
In an <a href="https://www.bloomberg.com/news/articles/2024-11-21/ken-griffin-says-he-s-open-to-selling-minority-stake-in-citadel">interview</a> with&nbsp;Bloomberg on Thursday at the Economic&nbsp;Club of New York, Griffin stated,&nbsp;"We would be open to&nbsp;the possibility of selling a&nbsp;minority stake in Citadel at&nbsp;some point in the future."
Griffin highlighted the challenges of public capital markets, stating,&nbsp;"We need to make being&nbsp;public in the United States&nbsp;a much more attractive proposition."&nbsp;
Despite the offer, Griffin did not confirm acceptance and ruled out taking Citadel Securities public soon. When considering potential partners, Griffin seeks firms similar to Sequoia that can enhance Citadel&#8217;s business operations.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42102652/michael-saylors-microstrategy-takes-wall-street-by-storm-becomes-second-most-traded-stock-after-nvidia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Michael Saylor&#8217;s MicroStrategy Takes Wall Street By Storm, Becomes Second-Most Traded Stock After Nvidia</a>
Why It Matters:&nbsp;Griffin, a prominent figure in the financial world, has built&nbsp;Citadel&nbsp;into a powerhouse with over $65 billion in assets. As a mega-donor to the Republican Party, he recently voiced concerns over&nbsp;<a href="https://www.benzinga.com/news/global/24/11/42056528/gop-megadonor-ken-griffin-warns-of-slippery-slope-in-trumps-tariff-policies-sees-us-returning-to-the-business-of-business">Donald Trump&#8216;s tariff policies</a>, warning they could hinder U.S. competitiveness. 
In the past year, Citadel has achieved remarkable financial success, <a href="https://www.benzinga.com/general/23/12/36365068/show-me-the-money-inside-ken-griffins-citadels-jaw-dropping-7-billion-return">returning $7 billion to clients </a>after a 30% profit surge. Citadel&#8217;s multistrategy fund, Wellington, has gained nearly 15% year-to-date, making it one of the top-performing hedge funds. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42102769/floki-beats-dogecoin-shiba-inu-with-double-digit-gains-after-coinbase-listing-announcement?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Floki Beats Dogecoin, Shiba Inu With Double-Digit Gains After Coinbase Listing Announcement</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo by Dan G via Flickr

GOP Megadonor Ken Griffin Is 'Open To The Possibility' Of Selling Minority Stake In Citadel

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index moved to the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled higher on Thursday, with the Dow Jomes index gaining more than 450 points during the session.
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose by 0.5% on Thursday after the company posted upbeat earnings and sales results. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell 2.2% on Thursday following a report suggesting the company is likely to be investigated under the EU&#8217;s Digital Markets Act next year.
Shares of Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) plunged around 4.7% following the U.S. Department of Justice&#8217;s (DOJ) announcement of sweeping remedies in its high-profile antitrust lawsuit against Google.
On the economic data front, U.S. existing home sales gained by 3.5% from the previous month to an annualized rate of 3.96 million in October. The Philadelphia Fed Manufacturing Index fell to -5.5 in November from 10.3 in the previous month, and compared to market estimates of 8. U.S. initial jobless claims declined by 6,000 from the previous week to 213,000 in the week ending Nov. 16.
Most sectors on the S&amp;P 500 closed on a positive note, with utilities, financials, and consumer staples stocks recording the biggest gains on Thursday. However, consumer discretionary and communication services stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 462 points to 43,870.35 on Thursday. The S&amp;P 500 rose 0.53% to 5,948.71, while the Nasdaq Composite rose 0.03% at 18,972.42 during Thursday's session.
Investors are awaiting earnings results from Destination XL Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) and Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 57.4, the index moved to the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 49.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42114009/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

AMZN

DXLG

GOOG

GOOGL

NVDA

Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To 'Greed' Zone

The gross proceeds to the Company from the offering are expected to be approximately $8.2 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures. The offering is expected to close on or about November 25, 2024, subject to the satisfaction of customary closing conditions.

MODD

Reported Earlier, Modular Medical Prices $8.2M Public Offering Of 5,450,573 Common Shares At $1.50/Share

The Company intends to use the net proceeds from the Offering for general corporate purposes, including funding future investments, making capital expenditures and funding working capital. The Company has granted the underwriters a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of Notes. The Notes will be issued in minimum denominations of $25.00 and integral multiples of $25.00 in excess thereof. The Offering is expected to close on November 27, 2024.

METC

Reported Earlier, Ramaco Resources Prices $50M Senior Unsecured Notes Offering At 8.375% Interest Due 2029

<ul>
<li>&nbsp;Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024&nbsp;</li>
<li>&nbsp;Milestone payment to be made to HUTCHMED from Takeda&nbsp;</li>
<li>Fruquintinib already launched in several regions including the United States, Europe and China&nbsp;</li>
</ul>

Reported Earlier, HUTCHMED Secures Milestone Payment As Takeda Rolls Out FRUZAQLA In Japanese Market

The New 4.625% Notes will bear interest at a rate of 4.625% per year, to be paid semi-annually on June 23 and December 23, commencing on June 23, 2025. The 9.875% Notes will bear interest at a rate of 9.875% per year, to be paid semi-annually on June 23 and December 23, commencing on June 23, 2025.

Reported Earlier, GrafTech Announces Exchange Offers For $500M And $450M Second Lien Notes Due 2029

With U.S. stock futures trading slightly lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Destination XL Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) to report quarterly earnings at 3 cents per share on revenue of $113.46 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Destination XL shares rose 0.8% to $2.60 in after-hours trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported better-than-expected earnings for its second quarter and raised its outlook for FY24 gross margin. The company reported quarterly earnings of 54 cents per share, which beat the analyst consensus estimate of 40 cents per share. Gap shares jumped 15.7% to $25.50 in the after-hours trading session.</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) posted stronger-than-expected earnings for its third quarter on Thursday. The company said it sees FY25 earnings of $6.10 to $6.17 per share. Ross Stores shares climbed 7.1% to $153.11 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Intuit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) reported upbeat results for its first-quarter results, but issued weak forecast for the current quarter. The company reported quarterly earnings of $2.50 per share, which beat the analyst consensus estimate of $2.35 per share. Quarterly revenue came in at $3.28 billion which beat the consensus estimate of $3.14 billion. Intuit shares fell 5% to $644.74 in the after-hours trading session.</li>
<li>Analysts expect Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) to report quarterly earnings at 3 cents per share on revenue of $127.50 million before the opening bell. Global Blue Group shares gained 11.4% to $6.96 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42114009/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields</a></li>
</ul>
Photo courtesy: Gap

INTU

ROST

Gap, Ross Stores And 3 Stocks To Watch Heading Into Friday

The 91 rating InvestorsObserver gives to Greenwich Lifesciences Inc (GLSI)  stock puts it near the top of the Healthcare sector.In addition to scoring higher than 100 percent of stocks in the Healthcare sector, GLSIâ€&#x2122;s 91 overall rating means the stock scores better than 91 of all stocks. GLSI has an Overall Score of 91. Fi

Will Greenwich Lifesciences Inc (GLSI) Outperform the Rest of the Stocks in the Healthcare Sector?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenwich LifeSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/glsi-stock-quote/">GLSI</a>) just reported results for the fourth quarter of 2023.<ul><li>Greenwich LifeSciences reported earnings per share of -21 cents. This was below the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/glsi-stock-earnings-greenwich-lifesciences-for-q4-of-2023/">GLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenwich LifeSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/glsi-stock-quote/">GLSI</a>) just reported results for the first quarter of 2024.<ul><li>Greenwich LifeSciences reported earnings per share of -19 cents. This was above the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/glsi-stock-earnings-greenwich-lifesciences-for-q1-of-2024/">GLSI Stock Earnings: Greenwich LifeSciences Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GLSI Stock Earnings: Greenwich LifeSciences Beats EPS for Q1 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Poseida Therapeutics (PSTX – Research Report), Green...

Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)

Greenwich LifeSciences raises $2.5M, issues shares to CEO

Greenwich LifeSciences to join Russell 2000 index

Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenwich LifeSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/glsi-stock-quote/">GLSI</a>) just reported results for the second quarter of 2024.<ul><li>Greenwich LifeSciences reported earnings per share of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/glsi-stock-earnings-greenwich-lifesciences-for-q2-of-2024/">GLSI Stock Earnings: Greenwich LifeSciences Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GLSI Stock Earnings: Greenwich LifeSciences Reported Results for Q2 2024

Greenwich LifeSciences files for $275M mixed securities shelf

PSTX

RHHBF

RHHBY

RHHVF

SLRN

Press Releases

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences Provides Update on Corporate Events

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Atossa Therapeutics

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Caribou Biosciences

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Gossamer Bio

Heron Therapeutics

Inozyme Pharma

Inventiva S.A. - American Depository Shares

Inventiva

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

PepGen

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Instil Bio

Tenaya Therapeutics

2seventy bio

Verastem

Zura Bio Limited - Class A Ordinary shares

Comments

Greenwich LifeSciences

Greenwich LifeSciences (GLSI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga